View Cart
Global Information, Inc.
US:
+1-860-674-8796
EU:
+32-2-535-7543
SG:
+65-6223-2436
Home
|
Category
|
Publishers
|
Custom Research
|
E-mail Alert
|
About Us
|
Contact Us
|
Site Map
|
Pharmaceutical
Drug Discovery
Drug Delivery System
Veterinary Medicine
Bone Disease Treatment
Obesity Treatment
Generic Drugs
OTC Drug
Prescription Drugs
Vaccines
Regulation
Cancer
Diabetes
Infection Disease
Mental Disease
Pharmaceutical Companies
Neurodegenerative Disease
View All Categories
Home
>
Category
>
Pharmaceutical
>
Market Research Report
INFLAMMATORY DIRECTIONS: Strategies for Six Diseases with Unmet Needs
Published by
Insight Pharma Reports
Published
2008/04
Content info
176 pages
Product code
CD64478
Price
From
US $ 2995
US $ 2995
Hard Copy
US $ 3750
PDF by E-mail (Single Site License)
How to Order?
PDF by E-Mail
Approx. 1-2 business days
Hard Copy/CD-ROM
Approx. 3-4 business days
If you need expedited delivery, please call us.
Table of Contents
Chapter 1 INTRODUCTION: THE IMMUNE SYSTEM AND THE INFLAMMATORY RESPONSE
1.1. The Immune System
1.2. Immune Dysfunction and Autoimmune Disease
Chapter 2 REVIEW OF THE INFLAMMATORY DISEASES: EPIDEMIOLOGY, PATHOLOGY, DIAGNOSIS, AND SYMPTOMS
2.1. Rheumatoid Arthritis
Pathology
Causes
Diagnosis
Epidemiology
2.2. Inflammatory Bowel Disease
Pathology
Causes
Diagnosis
Epidemiology
2.3. Psoriasis
Pathology
Causes
Diagnosis
Epidemiology
2.4. Lupus
Pathology
Causes
Diagnosis
Epidemiology
2.5. Multiple Sclerosis
Pathology
Causes
Diagnosis
Epidemiology
2.6. Asthma
Pathology
Causes
Diagnosis
Epidemiology
Chapter 3 CURRENT PHARMACOLOGICAL TREATMENT OPTIONS
3.1. Rheumatoid Arthritis
Analgesics and NSAIDS
Corticosteroids
Synthetic DMARDs
Methotrexate
Arava (Leflunomide)
Other DMARDs
Biological DMARDs
Enbrel (Etanercept)
Remicade (Infliximab)
Humira (Adalimumab)
Kineret (Anakinra)
Orencia (Abatacept)
Rituxan (Rituximab)
3.2. Inflammatory Bowel Disease
Aminosalicylates
Corticosteroids
Immunomodulators
Azathioprine, 6-Mercaptopurine, and 6-Thioguanine
Methotrexate
Cyclosporine
Remicade (Infliximab)
Humira (Adalimumab)
Tysabri (Natalizumab)
Antibiotics
3.3. Psoriasis
Topical Therapies
Corticosteroids
Vitamin D3 and A Compounds
Retinoids
Coal Tar
Anthralin
Salicylic Acid
Light Therapy
Systemic Therapy
Methotrexate
Cyclosporine
Oral Retinoids
Hydroxyurea
Amevive (Alefacept)
Raptiva (Efalizumab)
Enbrel (Etanercept)
Remicade (Infliximab)
Humira (Adalimumab)
3.4. Lupus
NSAIDs
Antimalarials
Corticosteroids
Immunomodulators
3.5. Multiple Sclerosis
Corticosteroids
Disease-Modifying Agents
Interferon Beta
Copaxone (Glatiramer Acetate)
Novantrone (Mitoxantrone)
Tysabri (Natalizumab)
Other Immunomodulators
3.6. Asthma
Quick-Relief Medications
Bronchodilators
Oral Corticosteroids
Long-Term Control Medications
Inhaled Corticosteroids
Bronchodilators
Mast Cell Stabilizers
Leukotriene Modifiers
Xolair (Omalizumab)
Chapter 4 COMPOUNDS IN DEVELOPMENT: THE NEXT GENERATION OF DRUGS FOR INFLAMMATORY DISEASES
4.1. New Approaches to Inflammatory Diseases
Tumor Necrosis Factor Family Inhibitors
Interleukin Inhibitors
Other Cytokine Inhibitors
Chemokine Receptor Antagonists
Anti-inflammatory Cytokines
Compounds Targeting T-Cell Antigens
Compounds Targeting B-Cell Antigens
Complement Inhibitors
Adhesion Molecule Blockers
Protease Inhibitors
TACE
ICE
Cathepsin S
Kinase Inhibitors
p38 MAP Kinase
JNK
NF-κB
Other Kinases
4.2. Setbacks
4.3. Rheumatoid Arthritis
TNF-alpha Inhibitors
UCB
Centocor
Targeted Genetics
Arana Therapeutics
Xencor
Meyer Pharmaceuticals
Pharmaxis
Ception Therapeutics
Ablynx
Nastech Pharmaceutical
Devgen
Interleukin Inhibitors
Amgen
Kinase Inhibitors
Rigel Pharmaceuticals
Plexxikon
4.4. Inflammatory Bowel Disease
Adhesion Molecule Blockers
Atlantic Healthcare
Millennium Pharmaceuticals
Other Compounds
InDex Pharmaceuticals
Genzyme
4.5. Psoriasis
TNF Inhibitors
Apollo Life Sciences
York Pharma
Interleukin Inhibitors
Centocor
Abbott Laboratories
Calcineurin Inhibitors
Isotechnika
Biogen Idec
CombinatoRx
Celgene
Vitamin D Analogs
CollaGenex Pharmaceuticals
Cytochroma
4.6. Lupus
Immunomodulators
La Jolla Pharmaceutical
Genelabs Technologies
BLyS Inhibitors
Human Genome Sciences
ZymoGenetics
Anthera Pharmaceuticals
Biogen Idec/Genentech
Xencor
Toll-like Receptor Antagonists
Coley Pharmaceutical Group
Dynavax Technologies
Idera Pharmaceuticals
4.7. Multiple Sclerosis
Immunomodulators
Biogen Idec
Genzyme/Bayer Schering Pharma
Novartis
Cytokines
Nastech Pharmaceutical
Syntonix Pharmaceuticals
Ichor Medical Systems
Nautilus Biotech
Flamel Technologies
Modigene
Bolder BioTechnology
CoGenesys
Allozyne
Peptide Vaccines and MBP-Base Therapeutics
Orchestra Therapeutics
BioMS Medical/Eli Lilly
Bayhill Therapeutics
Remyelinating Agents
Biogen Idec
Acorda Therapeutics
4.8. Asthma
Interleukin Inhibitors
GlaxoSmithKline
MedImmune/BioWa
Aerovance
Amgen
Genentech
Altair Therapeutics
CSL/Merck
Synairgen
Phosphodiesterase-4 Inhibitors
Nycomed
Glenmark Pharmaceuticals/Forest Laboratories
MediciNova
Other PDE4 Inhibitors
Toll-like Receptor Agonists
Coley Pharmaceutical Group/Sanofi-Aventis
Dynavax Technologies
Idera Pharmaceuticals
InDex Pharmaceuticals
CRTH2 Antagonists
References
Company Index with Web Addresses
Related Report
Antiviral Therapeutics - technologies, markets and companies
Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
Autoimmune Treatment (2009 - 2014)
Autoimmune Disease Therapeutics
Alzheimer disease - new drugs, markets and companies
Please inform me when related publications are released
US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2009, the-infoshop.com by Global Information, Inc. All rights reserved.